Abstract
Aurora kinases are a group of serine/threonine kinases responsible for the regulation of mitosis. In recent years, with the increase in Aurora kinase-related research, the important role of Aurora kinases in tumorigenesis has been gradually recognized. Aurora kinases have been regarded as a new target for cancer therapy, resulting in the development of Aurora kinase inhibitors. The study and application of these small-molecule inhibitors, especially in combination with chemotherapy drugs, represent a new direction in cancer treatment. This paper reviews studies on Aurora kinases from recent years, including studies of their biological function, their relationship with tumor progression, and their inhibitors.
Keywords: Aurora kinases, Mitosis, Head and neck cancer, Aurora kinase inhibitor, Tumor, Biological function.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Aurora Kinase Inhibitors in Head and Neck Cancer
Volume: 18 Issue: 3
Author(s): Guangying Qi, Jing Liu, Sisi Mi, Takaaki Tsunematsu, Shengjian Jin, Wenhua Shao, Tian Liu, Naozumi Ishimaru, Bo Tang*Yasusei Kudo*
Affiliation:
- Department of Pathology and Physiopathology, Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, 541000,China
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8504,Japan
Keywords: Aurora kinases, Mitosis, Head and neck cancer, Aurora kinase inhibitor, Tumor, Biological function.
Abstract: Aurora kinases are a group of serine/threonine kinases responsible for the regulation of mitosis. In recent years, with the increase in Aurora kinase-related research, the important role of Aurora kinases in tumorigenesis has been gradually recognized. Aurora kinases have been regarded as a new target for cancer therapy, resulting in the development of Aurora kinase inhibitors. The study and application of these small-molecule inhibitors, especially in combination with chemotherapy drugs, represent a new direction in cancer treatment. This paper reviews studies on Aurora kinases from recent years, including studies of their biological function, their relationship with tumor progression, and their inhibitors.
Export Options
About this article
Cite this article as:
Qi Guangying , Liu Jing , Mi Sisi , Tsunematsu Takaaki , Jin Shengjian , Shao Wenhua , Liu Tian , Ishimaru Naozumi , Tang Bo *, Kudo Yasusei *, Aurora Kinase Inhibitors in Head and Neck Cancer, Current Topics in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1568026618666180112163741
DOI https://dx.doi.org/10.2174/1568026618666180112163741 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy
Current Drug Targets Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy
Current Drug Targets Recent Advances of MEK Inhibitors and Their Clinical Progress
Current Topics in Medicinal Chemistry Cytotoxicity of Sodium Arsenite-loaded Anti-HER2 Immunoliposomes Against HER2-expressing Human Breast Cancer Cell Lines
Letters in Drug Design & Discovery Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma
Current Pharmaceutical Design Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Pharmacokinetics-Guided Dosing of 5-Fluorouracil for Precision Cancer Treatment: A Focus on Colorectal Carcinoma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design The Role of Cdc25A in the Regulation of Cell Proliferation and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets